An EEG Study of Intravenous Ketamine for Major Depression Disorder

This open-label trial (n=35) will assess the electroencephalographic (EEG) responses before, during, and after low-dose intravenous ketamine infusions over four weeks in patients with major depressive disorder (MDD).

The study aims to characterise changes in EEG readings, including frequencies, waveforms, amplitudes, and patterns, during the ketamine infusion and up to 4 weeks post-treatment. Patients will receive four weekly infusions of 60mg ketamine hydrochloride.

Primary outcomes include changes in EEG readings from baseline, and secondary outcomes focus on physiological parameters like blood pressure, heart rate, and oxygen saturation, along with changes in dissociative experiences. Participants must be between 18 and 70 years old, have a documented diagnosis of MDD, and meet specific screening criteria.

The study is conducted by Tristar Wellness and sponsored by Ehave Inc. Contact details for the study are provided, and enrollment is estimated to occur from January 2023 to January 2024.

Topic Depression
Compound Ketamine
Country Canada
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Ehave
Ehave is playing a main job in the advancement of computerized therapeutics by making an extensible stage whereupon amazing, condition-explicit applications can be planned, fabricated, clinically approved, and sent.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.